Patient P-02151
Therapy response
Stable
Tolerance
Improving
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
55%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S04
- Day 63 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient accepted — Started CR-01 in the companion
- Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 63.
Primary contributors, last 14 days
- Treatment adherence+7
- Toxicity-7
- Inflammatory activity-6
- GI instability-5
- Nutritional resilience+3
What helped?
- Clinician Review CR-01Day 122Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
58%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 5.9 h, below personal baseline
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- WearableHRV 23 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 19 ms
- Sleep
- 6.7 h
- Steps
- 5,895
- Resting HR
- 83 bpm
Daily log: GI score 56, nutritional resilience 40, adherence 67.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.